Dyax Corp. has appointed Abbie Celniker, Ph.D., to its Board of Directors.
“Abbie brings nearly three decades of business and scientific leadership in the biotechnology and pharmaceutical industries to Dyax, with a proven track record of successfully developing and commercializing life science products,” said Henry E. Blair, Chairman of Dyax’s Board of Directors. “Her expertise in advancing late-stage protein therapeutic discovery and development programs will provide the Board with a new and valued perspective as we develop DX-2930 and build our internal pipeline. We are delighted to welcome her to Dyax’s Board.”
Dr. Celniker currently serves as the President and CEO of Eleven Biotherapeutics, where she also serves on its Board of Directors. She holds a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.
(Source: Dyax Corp.)
